HC Wainwright Reaffirms “Buy” Rating for PDS Biotechnology (NASDAQ:PDSB)

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $21.00 price target on the stock.

Several other brokerages have also weighed in on PDSB. B. Riley decreased their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a buy rating on the stock in a research report on Wednesday. StockNews.com downgraded shares of PDS Biotechnology from a hold rating to a sell rating in a report on Saturday, March 16th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of PDS Biotechnology in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, PDS Biotechnology presently has an average rating of Moderate Buy and a consensus price target of $16.67.

PDS Biotechnology Price Performance

Shares of PDS Biotechnology stock opened at $2.79 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.56 and a current ratio of 4.56. The firm’s 50-day simple moving average is $3.22 and its 200-day simple moving average is $4.41. PDS Biotechnology has a twelve month low of $2.59 and a twelve month high of $6.85. The firm has a market cap of $102.15 million, a P/E ratio of -2.05 and a beta of 1.82.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, May 15th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.07. As a group, research analysts expect that PDS Biotechnology will post -1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently added to or reduced their stakes in PDSB. Vanguard Group Inc. raised its stake in shares of PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after acquiring an additional 82,135 shares during the last quarter. Kathleen S. Wright Associates Inc. bought a new position in shares of PDS Biotechnology in the first quarter worth about $28,000. Inspirion Wealth Advisors LLC raised its stake in shares of PDS Biotechnology by 5.5% in the first quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock worth $1,406,000 after acquiring an additional 18,383 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of PDS Biotechnology by 530.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock worth $45,000 after acquiring an additional 7,612 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of PDS Biotechnology in the fourth quarter worth about $52,000. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.